When used for obesity, the results are even more dramaticpeople taking semaglutide, the active ingredient in Ozempic, for instance, report an average weight loss of 12.7 kg (nearly 28 pounds) over 68 weeks compared to a placebo
doi: 10.1161/CIRCRESAHA.116.303577 204 PrestaI.VismaraM.NovellinoF.DonatoA.ZaffinoP.ScaliE.et al
Return and retest policy: Reputable vendors clearly state what happens if a vial arrives damaged, appears underfilled, or reconstitutes abnormally
Given the increasing availability of CV safety outcomes data for glucose-lowering medications, it has become apparent that certain agents within the GLP-1RA and SGLT-2 inhibitor classes reduce the risk of CV events in those with high-risk CV or CKD [16,17,18,19,20,21]